Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

r oral administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing, or elicit signs of addiction in animal models. CR845 and related compounds are covered by a recently issued U.S. patent.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen(TM) technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... NEW YORK, Jan. 25, 2011 Reportlinker.com ... is available in its catalogue: ... analysis of small molecule brand erosion post-patent ... IntroductionPharma is facing slowing ...
... 2011 Prolong Pharmaceuticals, which in October secured a ... today announced the signing of a long term lease ... and the formal addition of Dr. Hemant Misra to ... and Facilities Operations. The manufacturing facility ...
Cached Medicine Technology:Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry 2Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team 2
(Date:7/12/2014)... As reported in this July 1st article ... the June 25th, 2014 Supreme Court ruling in Riley v ... It was also met with both cheers and jeers when ... seen from an individual privacy perspective, or a law enforcement ... now precedent which will require law enforcement officials to obtain ...
(Date:7/12/2014)... July 12, 2014 Praeclarus Press ... Simple as a valuable new resource for women in ... of American women work away from their children. Today’s ... the benefits of breastfeeding, but often feel unsupported when ... their babies. With its evidence-based insights, and written by ...
(Date:7/12/2014)... Palm Beach, FL (PRWEB) July 12, 2014 ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... 2014 Recently, DressyQuinceanera.com, a well-known wedding ... Dama dresses to its online category. Furthermore, the ... at deeply discounted rates, up to 62% off. , ... equally excellent in terms of quality and style. All ... discounts are also offered for the company’s other items: ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 As ... filed against Johnson & Johnson’s Ethicon Inc. unit ... LLP notes that the Texas Attorney General’s Office ... marketing of surgical mesh products used to treat ... to a report from kens5.com, the probe began ...
Breaking Medicine News(10 mins):Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, ... temporarily zaps away forehead wrinkles by freezing the nerves ... The technique, if eventually approved by the U.S. Food ... and Dysport. Both are injectable forms of Botulinum toxin ...
... April 2011: Exciting new data presented today at the ... chronic hepatitis C (HCV) patients suppressed the emergence of ... sustained virological response - undetectable HCV RNA - 12 ... study, HCV patients were given four drugs in combination; ...
... on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer ... and presented updated results at the AACR 102nd Annual ... Heymach, M.D., Ph.D., associate professor of thoracic, head and neck ... Center, said this update details the "discovery phase" of the ...
... April 1 (HealthDay News) -- It,s important to keep injury ... Dr. Steven Greer, of the MCGHealth Sports Medicine Center in ... children. All children should undergo a physical examination before ... an extended period of time, they should begin increasing ...
... April 1 (HealthDay News) -- Updated guidelines to keep children ... released this week by the American Academy of Pediatrics. ... interests, skills and overall well-being, to ensure their child can ... to medically and mentally prepare their child for camp, and ...
... scientific discoveries in children,s health will be presented in Denver ... the Pediatric Academic Societies (PAS). This year,s gathering is a ... and more than 6,500 leaders in academic pediatrics from around ... Colorado Convention Center. Journalists will have access to ...
Cached Medicine News:Health News:Freezing Wrinkles a Possible Alternative to Botox 2Health News:Freezing Wrinkles a Possible Alternative to Botox 3Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:BATTLE researchers identify new biomarkers for EGFR inhibition 2Health News:Tips for Keeping Young Athletes Safe 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2Health News:Children's health is focus of annual meeting of Pediatric Academic Societies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: